Design Therapeutics (DSGN) Total Liabilities (2020 - 2026)

Design Therapeutics has disclosed Total Liabilities across 7 years of filings, most recently posting $12.4 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $12.4 million, up 29.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (up 29.64% YoY), and the FY2025 annual result was $13.7 million, up 37.05% from the prior year.
• Total Liabilities came in at $12.4 million for Q1 2026 at Design Therapeutics, down from $13.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $14.9 million in Q3 2023 to a low of $8.3 million in Q2 2024.
• The 5-year median for Total Liabilities is $11.9 million (2023), against an average of $11.4 million.
• Across the five-year window, Total Liabilities soared 203.78% in 2022 and sank 43.78% in 2024, its largest moves.
• Design Therapeutics' Total Liabilities stood at $13.8 million in 2022, then declined by 13.53% to $12.0 million in 2023, then slipped by 16.39% to $10.0 million in 2024, then soared by 37.05% to $13.7 million in 2025, then retreated by 9.58% to $12.4 million in 2026.
• The last three Total Liabilities figures came in at $12.4 million (Q1 2026), $13.7 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.